Our Products
Imunomedicor is a biopharmaceutical company focused on discovering, developing, licensing and commercializing innovative biotechnology products - all derived from nature.
Our initial research and development focus is on Imucore IM-039 and its’ significance as a part of the treatement of Melanoma Cancer. We expect our other innovative products to play a vital role in the development of genetically engineered pharmaceuticals and to also address urgent needs for:
• Effective treatments for HIV/AIDS;
•
Effective treatment for other new forms of cancer;
•
New antibiotics;
• Advances in Neuroscience;
Our initial goal is to develop IM-039-CAN as a Melanoma Cancer treatment followed by further development of IM-039 as a treatment modality for other diseases.
The exciting news about IM-039-CAN is it is not anticipated to be
harmfull at
all to healthy
human cells. IM-039-CAN will completely isolate the healthy cells
from the non-healthy cells and will prevent no further copies of
the Cancer cells
to be produced. Since IM-039-CAN will be directed specifically
against the Cancer cells and no others, as well as being non-toxic,
there
are
anticipated to be few if any side-effects observed in clinical
trials.
Our future developmet will be with the treatement of HIV and other viruses.
The IM-039-HIV product will remove the HIV virus’ ability
to replicate without affecting healthy cells.
The technology that IM-039 is based upon will allow Immunomedicor to research and develop a whole new line of novel molecules, never seen by man, to sustain, improve and prolong human life. For more details on our current product research and development, please visit our Research page.
Please take a look at our 3 separate product videos below.
|
|
| 1. On initial funding we will complete a research
grant to improve the process
by which the IM-039 is separated from its raw material. We will also
sign the lease on the laboratory facility and begin installation
of the equipment critical to the separation and characterization
of the IM-039 from its raw material. Timing: first 30 days. 2. In approximately 30 days from the lease signing, we should have the first
sections of the lab operational and ready to begin the process of separation
and characterization of the IM-039 from its raw material. 3. After about four weeks of work on the separation, we should have enough
working material to begin the first stages of the preclinical work. 4. Small amounts of the IM-039 will be shipped to a contract facility to begin
the humanization of IM-039. 5. After roughly 15 weeks of development, the humanized version of IM-039
will be ready for testing for toxicity, affinity and effectiveness. 6. One week after completion of the humanized IM-039, we should be ready to
file for patents in both the US and Mexico. 7. Immediately following the filing of the patent applications, we will begin
in vitro testing of the IM-039 against various cancer lines. 8. After approximately 30 days, we should be able to start our preclinical
small animal studies. 9. Once we have concluded the small animal studies, we should be able to file
our “Innovative New Drug” (IND) application with the FDA. 10. As we conclude our small animal studies and show no toxicity and good
affinity plus effectiveness, we may begin clinical trials in a foreign country. |
